

# PHYSICIANS HEALTH CHOICE

PHYSICIANS HEALTH CHOICE GUIDELINES		
Title: <p style="text-align: center;"><b>Diabetes Mellitus Guidelines</b></p>	Purpose: Maximize the Management and Outcomes of Members with Diabetes	PAC Review/Approval Date:  QIC Approval Date:
Author: Nancy Erickson, RN		
Medical Director Review: P. Terrence Nugent, MD		
Date of Last Review: 12/08/03		

ASSESSMENT	RECOMMENDATIONS
<b>Routine Visits</b>	Quarterly, until achievement of treatment goals.  More frequent visits are required if not meeting glycemic target, BP is not controlled, or there is evidence of microvascular or macrovascular complications and/or undergoing intensive insulin therapy.
<b>Weight</b>	Every routine visit
<b>Glycosylated Hb (A1C)</b> <b>HEDIS:</b> Annual testing	Annually or semi-annually Target Goal of $\leq 7\%$ Reevaluate treatment regimen for patients with Hb $> 8\%$ Quarterly

## PHYSICIANS HEALTH CHOICE

ASSESSMENT	RECOMMENDATIONS
<b>Blood Pressure</b> <b>HEDIS</b>	<ul style="list-style-type: none"> <li>• Every routine visit with a target goal of &lt; 130/80</li> <li>• Patients with systolic between 130-139 and diastolic between 80-89 should be given lifestyle/ behavior therapy alone for a maximum of three months, and then if targets not achieved should be treated pharmacologically.</li> <li>• Patients with hypertension (systolic blood pressure &gt;140 or diastolic blood pressure &gt;90) should receive drug therapy in addition to lifestyle/behavior therapy.</li> <li>• Initial drug therapy may include ACE, ARB, BB or diuretics.</li> <li>• In hypertensive patients with Microalbuminuria, or clinical albuminuria/nephropathy, an ACE should be considered.</li> <li>• In patients over age 55 yrs, with HTN, or another cardiovascular risk factor, ACE should be considered to reduce risk of cardiovascular events.</li> <li>• In patients with recent MI, BB, in addition, should be considered to reduce mortality.</li> </ul>
<b>Foot Exam</b> <b>HEDIS</b>	<p>Visual inspection at every contact with health care professional is required</p> <p>Comprehensive exam should be performed annually to identify high-risk foot conditions. Assessment should include:</p> <ul style="list-style-type: none"> <li>▪ Protective sensation, foot structure and biomechanics, neurological, vascular status and skin integrity.</li> <li>▪ Neurological status includes quantitative somatosensory threshold test using monofilament, vibratory sensation or Vibration Perception Threshold (VPT) Meter.</li> </ul>
<b>Dilated Retinal Exam</b> <b>HEDIS:</b> one during reporting year, or year prior for low-risk patients	<p>Annual comprehensive dilated exam by ophthalmologist or optometrist:</p> <ul style="list-style-type: none"> <li>• For all patients &gt;12 years old and who have had DM for 5 years</li> <li>• All patients &gt; age 30</li> <li>• Any patient with visual symptoms</li> </ul>

## PHYSICIANS HEALTH CHOICE

ASSESSMENT	RECOMMENDATIONS
<p><b>Blood Lipids</b>  <b>HEDIS:</b> tested once during reporting year or year prior; looking for LDL &lt; 100mg/dl</p>	<p>All adults should be tested initially and annually thereafter. Tests should be performed in a fasting state and should include:</p> <p style="text-align: center;"><b>Goal</b></p> <ul style="list-style-type: none"> <li>• Cholesterol &lt;200mg/dl</li> <li>• Triglyceride &lt;150mg/dl</li> <li>• HDL &gt;45mg/dl</li> <li>• LDL &lt;100mg/dl</li> </ul> <p>If all values are normal, clinician may consider performing less frequently. Abnormal values requiring therapy should follow NCEP recommendations:</p> <ol style="list-style-type: none"> <li>1. Advise all DM patients with CAD to follow the Low Fat, Low Sugar diet</li> <li>2. LDL: Lowering LDL is associated with a reduction in cardiovascular events. If LDL &gt; 100 mg/dl despite diet management, consider adding drug therapy. Use statins as first line pharmacotherapy for LDL lowering.</li> <li>3. Prescribe to patients with LDL &gt;100 mg/dl despite diet management. The goal of therapy is to reduce the LDL to &lt;100md/dl.</li> <li>4. If HDL &lt;35 mg/dl, emphasize weight management and increasing physical activity.</li> </ol>

## PHYSICIANS HEALTH CHOICE

ASSESSMENT	RECOMMENDATIONS	
<b>Nephropathy:</b> <b>HEDIS:</b> Monitoring evidence	Optimize glucose and blood pressure control to minimize risk and/or slow progression of nephropathy. Screen for nephropathy annually: Type I begin at puberty and > 5 years post diagnosis, then annually. Type II at time of diagnosis, then annually. Testing should include: <ul style="list-style-type: none"> <li>• Routine urinalysis annually</li> <li>• If protein is positive, a 24-hour quantitative measure is often helpful</li> <li>• If U/A is protein negative, perform Microalbumin test</li> <li>• Microalbuminuria testing can be performed by any of the following:               <ol style="list-style-type: none"> <li>1. Urine albumin/creatinine ratio in a random spot collection</li> <li>2. 24-hour collection with creatinine clearance time collection.</li> <li>3. If Microalbumin positive, repeat twice within three months.</li> <li>4. If still positive, begin treatment with ACE inhibitors.</li> </ol> </li> </ul>	
MEDICATIONS		
<b>Angiotensin –Converting Enzymes (ACE) Inhibitor Use</b>	<ul style="list-style-type: none"> <li>• Unless contraindicated, as primary treatment for all hypertensive patients (BP &gt; 140/90) with or without Microalbuminuria, or overt nephropathy.</li> <li>• Unless contraindicated, initial agents for all Type I patients with Microalbuminuria or clinical albuminuria, even if normotensive</li> <li>• All patients over 55 with or without hypertension, but with another cardiovascular risk factor should be considered.</li> </ul>	
<b>Angiotensin Receptor Blockers (ARBs)</b>	Initial agents of choice in hypertensive type 2 patients with Microalbuminuria or clinical albuminuria, or those who have not tolerated or failed ACE	
<b>Aspirin Therapy</b>	<ul style="list-style-type: none"> <li>• Use 75mg to 325 mg in all adult patients with diabetes and macrovascular disease.</li> <li>• Consider beginning therapy for primary prevention in patients &gt;40 yrs with diabetes and one more cardiovascular risk factor</li> </ul>	
<b>Diabetic Agents</b>	Insulin and oral agent therapy based on recommendations from P&T committee	
IMMUNIZATIONS	RECOMMENDATION	COMMENTS
<b>Influenza Vaccination</b>	Annually	See Preventive Health Guideline

## PHYSICIANS HEALTH CHOICE

ASSESSMENT	RECOMMENDATIONS	
<b>Pneumococcal Vaccination</b>	All adults 65 and older with competent immune systems	See Preventive Health Guideline
COUNSELING	RECOMMENDATION	COMMENTS
<b>Self-Management Training and Education</b> <b>Focus to include, but not limited to the following:</b> <ul style="list-style-type: none"> <li>• Referral to WellMed Diabetic Educator</li> <li>• Nutrition Counseling</li> <li>• Exercise and Physical Activity</li> <li>• Weight Management</li> <li>• Importance of Foot Care</li> </ul>	Every routine visit, conduct an assessment to evaluate patient's: <ul style="list-style-type: none"> <li>• Status</li> <li>• Compliance</li> <li>• Nutrition and Exercise Regimen</li> </ul> Annually to include: <ul style="list-style-type: none"> <li>• Diabetes knowledge</li> <li>• Self-Management Skills</li> <li>• Review of treatment plan, progress, and revise with patient as needed.</li> </ul>	<ul style="list-style-type: none"> <li>• Nutrition therapy may be more effective with individualized medical nutrition therapy provided by a CDE or a registered dietitian familiar with the components of diabetes medical nutrition therapy</li> <li>• A regular activity program, adapted to the presence of complications is recommended for all patients with diabetes who are capable of participating.</li> </ul>
<b>Smoking Cessation for smokers</b> <b>HEDIS</b>	Each visit Advise all patients on smoking cessation	

**REFERENCES:**

ADA, NIH, NHLBI, NCEP, AHCPR 2002